Cobalis Changes Its Trading Symbol From "CBSC" to "CLSC" - Update on Mandatory Share Certificate Exchange

Cobalis Changes Its Trading Symbol From "CBSC" to "CLSC" - Update
on Mandatory Share Certificate Exchange 


IRVINE, Calif., Aug. 27  /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CBSC)
(BULLETIN BOARD: CBSC) , a pharmaceutical company specializing in the
development of anti-allergy medications, announced today that its trading
symbol has changed to CLSC effective with the start of trading on Friday August
27, 2004.  The symbol change has been done to comply with NASDAQ rules
regarding ongoing mandatory share certificate exchange.

Concurrently, effective August 27, 2004, the Company's trading will temporarily
change to a "when issued" status, symbolized by a "V" added to the end of the
ticker symbol (CLSCV), to alert and allow sufficient time for brokerages,
clearing houses and investors to exchange the Company's stock certificates for
new certificates bearing the new Company name, CUSIP number and names of the
beneficial owners. This means that the stock will be trading with open-ended
settlement until NASDAQ determines that a sufficient number of the new shares
are outstanding and trading in the marketplace.

Brokers: please refer to NASDAQ's August 26, 2004 UNIFORM PRACTICE ADVISORY UPC
#093-2004.

While the stock is in a "when issued" status, the SEC T+3 requirement for
settlement of trades within three business days is suspended. As soon as the
"when issued" status is removed, the "V" will be removed from the ticker symbol
and all unsettled trades will require immediate settlement. All trades will
then be required to comply with T+3 settlement rules.

MANDATORY SHARE EXCHANGE

Effective August 27, 2004, as part of the name change, the CUSIP number change
and trading symbol change, all issued and outstanding shares in the name of
BioGentech Corp., with the CUSIP number 09063N104, and all issued and
outstanding shares in the name of Cobalis Corp., with the CUSIP number
19074Y106, MUST be exchanged for new certificates in the name of Cobalis Corp.
with the CUSIP number 19074Y205, and the name of the beneficial owner, or these
shares will be void, shall not entitle the certificate holder to any of the
rights of a shareholder of the Company, and shall be deemed worthless,
non-transferable and non-tradable in any public or private market or exchange
after October 12, 2004.

For more information regarding the mandatory share exchange, please refer to
the Company's Press Release dated August 23, 2004, and/or the Company's website
http://www.cobalis.com/.

"We thank our shareholders, the transfer agent, and the brokerage community for
their patience and support during the mandatory certificate exchange
procedure," noted Chas Radovich, Cobalis' President and CEO. "We understand
that this is a time-consuming task for all involved, but it is a necessary part
of our effort to protect and enhance shareholder value and to ensure the
security of all legitimate shareholders of the Company."

ABOUT COBALIS CORP. - PREHISTIN(TM)

Headquartered in Irvine, California, Cobalis Corp. is an over-the-counter
pharmaceutical company. Its flagship product, PreHistin, designed to prevent
the primary cause of airborne allergies, is scheduled for Phase III clinical
trials in late 2004 and initial marketing in the U.S. will commence upon final
FDA marketing approval. The U.S. anti-allergy medication market was $7.2
billion in 2003 and is expected to exceed $10 billion by 2010. PreHistin, "the
world's first pre-histamine," has shown in previous clinical studies to
modulate the body's level of the protein IgE, reducing the overproduction of
histamines, the primary cause of airborne allergy symptoms. Prior studies have
shown that the active ingredient in PreHistin appears to have essentially no
risks of adverse effects to the general population, including sedation and
drowsiness found in many of the allergy products currently available.

For further information please visit the website at http://www.cobalis.com/. 

DATASOURCE: Cobalis Corp.



CONTACT:  Chaslav Radovich, President & CEO, [phone], or fax,

[phone], or , or Bo Cosic, [phone], or

cell, [phone], or fax, [phone], or , both of

Cobalis Corp.



Web site:  http://www.cobalis.com/ 

Copyright